한국형 우울장애 약물치료 알고리듬 2017(Ⅵ) : 안정성, 부작용, 동반 신체질환을 고려한 항우울제 선택 = Korean Medication Algorithm for Depressive Disorder 2017(VI) : Antidepressant Choices According to Safety, Adverse Event and Comorbid Physical Illnesses

다국어 초록 (Multilingual Abstract)

Objectives : This study was undertaken to revise guidelines for the Korean Medication Algorithm Projects for Depressive Disorder 2012 (KMAP-DD 2012). The main purpose of the current study was a revision of the antidepressant choices based on their safety, adverse events and comorbid physical illnesses. Methods : A 44-item questionnaire was developed ; an expert consensus was obtained on the pharmacological treatment strategies regarding the choice of an antidepressant (AD), with respect to its safety and adverse effects. Multiple response sets were used for statistical analysis. Results : Our results showed the 1st line of treatment for various afflictions were as follows: Bupropion (sexual dysfunction), Fluoxetine (sedation), Mirtazapine (control of sleep disturbance and nausea), and Escitalopram (for patients with anticholinergic side effects). For patients exhibiting comorbid conditions, escitalopram was the 1st line of recommendation for diabetes, thyroid disease, liver disease and kidney disease. Conclusion : The pharmacological treatment strategy of KMAP-DD 2017 is similar to KMAP-DD 2012. Particularly noteworthy is that escitalopram was recommended for most of the medical comorbid conditions.

참고문헌 (Reference)

1 서정석, "한국형 우울장애 약물치료 알고리듬 2006 (Ⅰ)" 대한신경정신의학회 46 (46): 453-460, 2007

2 Kelly K, "Toward achieving optimal response:understanding and managing antidepressant side effects" 10 : 409-418, 2008

3 Boyer EW, "The serotonin syndrome" 352 : 1112-1120, 2005

4 Rudolph RL, "The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database" 16 : 54S-59S, 1996

5 Ali S, "The prevalence of co-morbid depression in adults with Type 2 diabetes: A systematic review and meta-analysis" 23 : 1165-1173, 2006

6 Lee MS, "The Korean Medication Algorithm for Major Depressive Disorder (KMAMDD):Report of the Korean Society of Depressive and Bipolar Disorders" 10 : 186-194, 2006

7 Bonierbale M, "The ELIXIR study: evaluation of sexual dysfunction in 4557 depressed patients in France" 19 : 114-124, 2003

8 Zalsman G, "Suicide prevention strategies revisited: 10-year systematic review" 3 : 646-659, 2016

9 Pacher P, "Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any?" 6 : 469-480, 1999

10 Rothschild AJ, "Sexual side effects of antidepressants" 61 (61): 28-36, 2000

11 Isbister GK, "Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose" 42 : 277-285, 2004

12 Ables AZ, "Prevention, recognition, and management of serotonin syndrome" 81 : 1139-1142, 2010

13 American Psychiatric Association, "Practice guideline for the treatment of patients with major depressive disorder"

14 Kim JM, "Physical comorbidity and 12-week treatment outcomes in Korean patients with depressive disorders: the CRESCEND study" 71 : 311-318, 2011

15 Kast RE, "Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy" 9 : 469-470, 2001

16 Thase ME, "Managing medical comorbidities in patients with depression to improve prognosis" 77 (77): 22-27, 2016

17 Jeong JH, "Korean Medication Algorithm for Bipolar Disorder 2014: Comparisons with other treatment guidelines" 11 : 1561-1571, 2015

18 Montejo AL, "Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction" 62 (62): 10-21, 2001

19 de Carvalho GA, "Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function" 19 : 691-697, 2009

20 Lustman PJ, "Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind, placebo-controlled trial" 59 : 241-250, 1997

21 Rosen RC, "Effects of SSRIs on sexual function:a critical review" 19 : 67-85, 1999

22 Buff DD, "Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease" 52 : 174-176, 1991

23 Stommel M, "Depression and functional status as predictors of death among cancer patients" 94 : 2719-2727, 2002

24 Hesslinger B, "Comorbidity of depressive disorders and cardiovascular diseases. Implications for diagnosis, pharmaco- and psychotherapy" 73 : 205-, 2002

25 Waring WS, "Clinical use of antidepressant therapy and associated cardiovascular risk" 4 : 93-101, 2012

26 Andrade C, "Cardiovascular mechanisms of SSRI drugs and their benefits and risks in ischemic heart disease and heart failure" 28 : 145-155, 2013

27 Kennedy SH, "Canadian Network for Mood and Anxiety Treatments (CANMAT)2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments" 61 : 540-560, 2016

28 Nezafati MH, "Antidepressants and cardiovascular adverse events: A narrative review" 11 : 295-304, 2015

29 Higgins A, "Antidepressant-associated sexual dysfunction: impact, effects, and treatment" 2 : 141-150, 2010

30 Alam A, "A review of therapeutic uses of mirtazapine in psychiatric and medical conditions" 15 : 10-, 2013